MA43416A - Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 - Google Patents
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3Info
- Publication number
- MA43416A MA43416A MA043416A MA43416A MA43416A MA 43416 A MA43416 A MA 43416A MA 043416 A MA043416 A MA 043416A MA 43416 A MA43416 A MA 43416A MA 43416 A MA43416 A MA 43416A
- Authority
- MA
- Morocco
- Prior art keywords
- erbb3
- slow
- growth
- methods
- prevent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266103P | 2015-12-11 | 2015-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43416A true MA43416A (fr) | 2018-10-17 |
Family
ID=57794340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043416A MA43416A (fr) | 2015-12-11 | 2016-12-09 | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180362654A1 (fr) |
| EP (1) | EP3387017A1 (fr) |
| JP (1) | JP2018536682A (fr) |
| CN (1) | CN108602890A (fr) |
| AU (1) | AU2016366521A1 (fr) |
| CA (1) | CA3007644A1 (fr) |
| MA (1) | MA43416A (fr) |
| WO (1) | WO2017100642A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| CN111670247B (zh) * | 2017-12-08 | 2024-01-05 | 京诊断株式会社 | 制备癌球状体的方法和选择结直肠癌患者的方法 |
| BR112020020273A2 (pt) | 2018-04-03 | 2021-04-06 | Blueprint Medicines Corporation | Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret |
| WO2020033838A2 (fr) * | 2018-08-10 | 2020-02-13 | Blueprint Medicines Corporation | Traitement du cancer à egfr mutant |
| KR102267593B1 (ko) * | 2018-10-19 | 2021-06-21 | 주식회사 프로티나 | Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법 |
| WO2020092924A1 (fr) * | 2018-11-02 | 2020-05-07 | Board Of Regents, The University Of Texas System | Polythérapie pour le traitement du cancer résistant aux inhibiteurs de la tyrosine kinase egfr |
| US20220008419A1 (en) * | 2018-11-14 | 2022-01-13 | Kanazawa Medical University | Pharmaceutical composition for treating diffuse-type gastric cancer |
| EP4157829A1 (fr) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Formes solide de pralsetinib |
| WO2022045976A1 (fr) * | 2020-08-25 | 2022-03-03 | Singapore Health Services Pte Ltd | Procédé de modulation de la sensibilité à un inhibiteur de tyrosine kinase |
| AU2021339962A1 (en) * | 2020-09-14 | 2023-05-25 | Janssen Pharmaceutica Nv | Fgfr inhibitor combination therapies |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0940468A1 (fr) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Domaine variable d'un anticorps humanisé |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| SI1680140T1 (sl) | 2003-10-16 | 2011-08-31 | Imclone Llc | Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi |
| EP1718667B1 (fr) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Liants et conjugues heterocycliques auto-immolateurs |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| DE502006007538D1 (de) | 2006-08-31 | 2010-09-09 | Treofan Germany Gmbh & Co Kg | Biaxial orientierte Elektroisolierfolie |
| US8236074B1 (en) | 2006-10-10 | 2012-08-07 | Us Synthetic Corporation | Superabrasive elements, methods of manufacturing, and drill bits including same |
| WO2008052796A1 (fr) | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Anticorps anti-fgfr4 |
| US8580263B2 (en) | 2006-11-21 | 2013-11-12 | The Regents Of The University Of California | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| PL2129396T3 (pl) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| WO2008122039A2 (fr) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molécules d'anticorps hybrides médiées par la sélénocystéine |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| WO2009117097A1 (fr) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Nouveaux inhibiteurs de tyrosine kinase |
| CN102083461B (zh) | 2008-04-30 | 2014-09-17 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
| FR2933702A1 (fr) | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| ES2536882T3 (es) | 2008-07-21 | 2015-05-29 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
| TWI381848B (zh) | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| EP3702371B1 (fr) | 2009-03-25 | 2022-11-02 | Genentech, Inc. | Anticorps anti-fgfr3 et procédés d'utilisation associés |
| AU2010242914B2 (en) | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
| EP2450055B1 (fr) | 2009-06-30 | 2018-01-03 | Obshestvo S OgranichennoyOtvetstvennostiu"OncoMax" | Procédé de prévention de la croissance de tumeurs du rein par blocage du récepteur du facteur de croissance de fibroblastes |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP2464654B1 (fr) | 2009-08-10 | 2014-10-08 | UCL Business PLC | Groupement protecteur thiol |
| CA2777242A1 (fr) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Agents de liaison bispecifiques qui ciblent la signalisation igf-1r et erbb3, et leurs utilisations |
| CA2782571C (fr) | 2009-12-22 | 2018-01-23 | Roche Glycart Ag | Anticorps anti-her3, et leurs utilisations |
| US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
| WO2011130598A1 (fr) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazépines et conjugués de celles-ci |
| AU2011254557B2 (en) | 2010-05-20 | 2015-09-03 | Ablynx Nv | Biological materials related to HER3 |
| WO2012005982A2 (fr) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Rapporteur pour une terminaison par la arn polymérase ii |
| WO2012015674A1 (fr) | 2010-07-26 | 2012-02-02 | Eli Lilly And Company | Utilisations thérapeutiques d'un anticorps anti-fgfr1c |
| PL2606070T3 (pl) | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| WO2012052230A1 (fr) | 2010-10-18 | 2012-04-26 | Mediapharma S.R.L. | Anticorps se liant à erbb3 |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| EP3156421B1 (fr) | 2010-11-01 | 2018-06-06 | Symphogen A/S | Composition d'anticorps pan-her |
| ITRM20100577A1 (it) | 2010-11-02 | 2012-05-03 | Takis Srl | Immunoterapia contro il recettore erbb-3 |
| RU2440142C1 (ru) | 2011-02-07 | 2012-01-20 | Общество С Ограниченной Ответственностью "Онкомакс" | Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований |
| MX342240B (es) | 2011-04-07 | 2016-09-21 | Genentech Inc | Anticuerpos anti-fgfr4 y metodos de uso. |
| KR20140138353A (ko) | 2011-04-19 | 2014-12-03 | 메리맥 파마슈티컬즈, 인크. | 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체 |
| PE20140995A1 (es) | 2011-05-16 | 2014-08-23 | Genentech Inc | Agonistas de fgfr1 y sus metodos de uso |
| EP2710040B1 (fr) | 2011-05-19 | 2017-07-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps anti-her3 humain et leurs utilisations |
| EP2714685B1 (fr) | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions contenant des dérivés de dolastatine liés à des acides aminés non naturel |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| AU2012274461A1 (en) | 2011-06-20 | 2014-01-16 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbB3 antibody |
| EP2736928B1 (fr) | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Proteines "sur"-liantes dirigees contre erbb3 |
| CA2849508C (fr) * | 2011-09-30 | 2020-12-22 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-erbb3 et leurs utilisations |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| AU2012318541B2 (en) | 2011-10-06 | 2018-04-12 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| MX358757B (es) | 2011-10-14 | 2018-09-03 | Seattle Genetics Inc | Pirrolobenzodiazepinas y conjugados dirigidos. |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
| EP2751076B1 (fr) | 2011-10-14 | 2018-04-25 | MedImmune Limited | Procédé de synthèse et intermédiaires pouvant servir à préparer des pyrrolobenzodiazépines |
| WO2013068874A1 (fr) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Conjugués anticorps-médicament |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| AU2012340766B2 (en) | 2011-11-23 | 2018-05-10 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| MX2014006739A (es) | 2011-12-05 | 2015-06-05 | Igenica Biotherapeutics Inc | Conjugados de anticuerpo-farmaco y compuestos relacionados, composiciones , y metodos. |
| AU2012349735B2 (en) | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| WO2013148315A1 (fr) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnostic et traitements concernant des inhibiteurs de her3 |
| BR112014025037A2 (pt) | 2012-04-09 | 2018-07-31 | Daiichi Sankyo Company, Limited | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente |
| TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| US20150202287A1 (en) | 2012-08-30 | 2015-07-23 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| SI2911699T2 (sl) | 2012-10-23 | 2026-01-30 | Synaffix B.V. | Modificirano protitelo, protitelo-konjugat in proces za njihovo pripravo |
| HK1214283A1 (zh) | 2012-10-25 | 2016-07-22 | Sorrento Therapeutics, Inc. | 與erbb3結合的抗原結合蛋白 |
| WO2014105849A1 (fr) | 2012-12-28 | 2014-07-03 | Xoma (Us) Llc | Anticorps spécifiques contre le fgfr4 et méthodes d'utilisation |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| RU2015137610A (ru) * | 2013-03-06 | 2017-04-10 | Дженентек, Инк. | Способы лечения и профилактики лекарственной резистентности злокачественных опухолей |
| JP2016520586A (ja) | 2013-05-08 | 2016-07-14 | ザイムワークス，インコーポレイテッド | 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| CN105593241B (zh) | 2013-10-04 | 2020-07-10 | 豪夫迈·罗氏有限公司 | 特异性结合her3的抗体 |
| WO2015066543A1 (fr) | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Ciblage de her2 et her3 avec des anticorps bispécifiques dans des cellules cancéreuses |
| KR102127408B1 (ko) | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
| CA2975829A1 (fr) | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage et administration d'anticorps bispecifiques anti-igf-1r et anti-erbb3, leurs utilisations et procedes de traitement les mettant en oeuvre |
| HRP20250041T1 (hr) | 2014-02-28 | 2025-03-14 | Merus N.V. | Antitijelo koje veže erbb-2 i erbb-3 |
| ES2816624T3 (es) | 2014-02-28 | 2021-04-05 | Merus Nv | Anticuerpos que se unen a EGFR y ERBB3 |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
| CA2944892A1 (fr) | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Anticorps bispecifiques anti her3/her2 se liant a l'epingle a cheveux beta de her3 et du domaine ii de her2 |
| US20170304313A1 (en) * | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
-
2016
- 2016-12-09 MA MA043416A patent/MA43416A/fr unknown
- 2016-12-09 JP JP2018529950A patent/JP2018536682A/ja active Pending
- 2016-12-09 EP EP16825935.6A patent/EP3387017A1/fr not_active Withdrawn
- 2016-12-09 WO PCT/US2016/065925 patent/WO2017100642A1/fr not_active Ceased
- 2016-12-09 CN CN201680080887.7A patent/CN108602890A/zh active Pending
- 2016-12-09 US US16/061,102 patent/US20180362654A1/en not_active Abandoned
- 2016-12-09 CA CA3007644A patent/CA3007644A1/fr not_active Abandoned
- 2016-12-09 AU AU2016366521A patent/AU2016366521A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN108602890A (zh) | 2018-09-28 |
| CA3007644A1 (fr) | 2017-06-15 |
| AU2016366521A1 (en) | 2018-06-21 |
| JP2018536682A (ja) | 2018-12-13 |
| WO2017100642A1 (fr) | 2017-06-15 |
| US20180362654A1 (en) | 2018-12-20 |
| EP3387017A1 (fr) | 2018-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43416A (fr) | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 | |
| IL272470A (en) | Methods and materials for assessing and treating cancer | |
| EP3695666A4 (fr) | Détection d'actions de conduite qui atténuent le risque | |
| EP3600281A4 (fr) | Traitement d'association pour le traitement ou la prévention de tumeurs | |
| MA71266A (fr) | Procédés d'intervention précoce pour prévenir ou améliorer la toxicité | |
| MA47310A (fr) | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer | |
| EP3353328A4 (fr) | Modulateurs de l'expression de kras | |
| EP3393475C0 (fr) | Ciforadent seul ou en combination avec l'atézolizumab pour son utilisaton dans le traitement du cancer | |
| EP3479493A4 (fr) | Détermination d'emplacements d'émetteur | |
| PL3411484T3 (pl) | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego | |
| IL248038B (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer | |
| MA49715A (fr) | Oligomères et conjugués d'oligomères | |
| EP3445213A4 (fr) | Système commandé d'infusion de boissons infusées | |
| EP3281579C0 (fr) | Identification de signaux ecg présentant une morphologie identique | |
| MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
| SI3720433T1 (sl) | Bis-holin tetratiomolibdat za zdravljenje Wilsonove bolezni | |
| MA53831A (fr) | Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques | |
| EP3500293A4 (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d | |
| IL262588A (en) | Humanized anti-basigin antibodies and the use thereof | |
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| EP3265115A4 (fr) | Utilisations d'un analogue de la pthrp pour réduire le risque de fractures | |
| EP3677266A4 (fr) | Inhibiteur sélectif de l'egfr muté sur l'exon 18 et/ou sur l'exon 21 | |
| EP2946139A4 (fr) | Revêtement dissimulé pour l'authentification de documents | |
| EP3472306A4 (fr) | Identification du facteur favorisant l'auto-renouvellement de hsc humaines | |
| EP3534944A4 (fr) | Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 |